PMID- 12565724
OWN - NLM
STAT- MEDLINE
DCOM- 20031014
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 107
IP  - 6
DP  - 2002 Sep 15
TI  - Effect of some new thioglycosides on endotoxin-induced disseminated intravascular 
      coagulation in rabbits.
PG  - 357-63
AB  - Disseminated intravascular coagulation (DIC) is a systemic thrombohemorrhagic 
      disorder seen in association with many clinical situations, e.g. sepsis, 
      malignancy, obstetrical complications and intravascular hemolysis. In our model, 
      disseminated intravascular coagulation was induced in rabbits by two consecutive 
      intravenous bolus injections of endotoxin from Escherichia coli, 80 and 40 
      microg/kg. The control group was treated with 0.9% saline. The activity of 
      thioglycosides was compared to unfractionated heparin (UFH) and efegatran with 
      and without administration of endotoxin. Drugs were administered in the following 
      doses: heparin 50 and 100 IU/kg/h i.v. infusion; efegatran 0.25 and 0.5 mg/kg/h 
      i.v. infusion; GYKI 39521 (RGH-1875) as well as GYKI 39541 (RGH-1962) 12.5 and 25 
      mg/kg per os. Thioglycosides did not modify coagulation parameters in this model 
      [prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin 
      time (TT)] as compared with endotoxin/vehicle group. The changes in TFPI level 
      after administration of thioglycosides and heparin were similar in the mentioned 
      model to those without endotoxin. Endotoxin-induced changes of leukocyte count 
      were not affected by GYKI 39521 and GYKI 39541 treatment in our model. Diminution 
      of fibrinogen level and platelet count was prevented by GYKI 39521 and GYKI 
      39541. Fibrin degradation products and fibrinolysis were significantly decreased 
      by GYKI 39521 and GYKI 39541. The thioglycosides may have a lower risk of 
      bleeding in the treatment of disseminated intravascular coagulation than heparin.
CI  - Copyright 2002 Elsevier Science Ltd.
FAU - Szabo, Gabriella
AU  - Szabo G
AD  - IVAX Drug Research Institute, PO Box 82, 1325 Budapest, Hungary.
FAU - Barabas, Eva
AU  - Barabas E
FAU - Kedves, Rita
AU  - Kedves R
FAU - Csomor, Katalin
AU  - Csomor K
FAU - Kuszmann, Janos
AU  - Kuszmann J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (4'-(methylthioiminomethyl)phenyl-1,5-dithioxylopyranoside)
RN  - 0 (4'-nitrophenyl-1,5-dithioarabinopyranoside)
RN  - 0 (Anticoagulants)
RN  - 0 (Endotoxins)
RN  - 0 (Oligopeptides)
RN  - 0 (Thioglycosides)
RN  - 67924-63-4 (endotoxin, Escherichia coli)
RN  - 9005-49-6 (Heparin)
RN  - VT0VK2474K (efegatran)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Disseminated Intravascular Coagulation/chemically induced/*drug therapy
MH  - Endotoxins/toxicity
MH  - Heparin/pharmacology
MH  - Male
MH  - Oligopeptides/pharmacology
MH  - Rabbits
MH  - Thioglycosides/*pharmacology
EDAT- 2003/02/05 04:00
MHDA- 2003/10/15 05:00
CRDT- 2003/02/05 04:00
PHST- 2003/02/05 04:00 [pubmed]
PHST- 2003/10/15 05:00 [medline]
PHST- 2003/02/05 04:00 [entrez]
AID - S0049384802003420 [pii]
AID - 10.1016/s0049-3848(02)00342-0 [doi]
PST - ppublish
SO  - Thromb Res. 2002 Sep 15;107(6):357-63. doi: 10.1016/s0049-3848(02)00342-0.